Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.93 USD | +0.42% | +18.97% | +13.70% |
18/04 | Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing | MT |
10/04 | ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept | MT |
Evolution of the average Target Price on ALX Oncology Holdings Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering ALX Oncology Holdings Inc.
UBS | |
HC Wainwright | |
Piper Sandler | |
Stifel Nicolaus | |
Jefferies & Co. | |
Cantor Fitzgerald | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- ALXO Stock
- Consensus ALX Oncology Holdings Inc.